ImmuPharma Loses Exclusivity Period For Talks With Incanthera

LONDON (Alliance News) - ImmuPharma PLC on Monday said proposed partner Incanthera Ltd can now talk with other potential parties after an exclusivity period ended.

In September, ImmuPharma announced a heads of terms with oncology firm Incanthera, as well as a purchase of 16% of the company for GBP2 million.

The two were also in talks over a licensing agreement for Incanthera's Nucant programme, but the exclusivity period for the discussions ended on Sunday.

"The company and Incanthera have to date not concluded the definitive licence agreement. The exclusivity period has now expired and ImmuPharma is free, should it wish, to discuss collaborations with other parties for the Nucant cancer programme," said ImmuPharma.

"Notwithstanding the expiry of the exclusivity period, discussions with Incanthera are continuing in good faith for a broader collaboration."

ImmuPharma shares were 8.8% lower on Monday at a price of 10.56 pence each.

Immupharma